RCN2 Rekombinanter Antikörper
RCN2 Rekombinant Antikörper für WB, IHC, IF/ICC, Indirect ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human, Maus, Ratte
Anwendung
WB, IHC, IF/ICC, Indirect ELISA
Konjugation
Unkonjugiert
CloneNo.
242612A4
Kat-Nr. : 84956-4-PBS
Synonyme
Geprüfte Anwendungen
Produktinformation
84956-4-PBS bindet in WB, IHC, IF/ICC, Indirect ELISA RCN2 und zeigt Reaktivität mit human, Maus, Ratten
| Getestete Reaktivität | human, Maus, Ratte |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Rekombinant |
| Typ | Antikörper |
| Immunogen | RCN2 fusion protein Ag0247 |
| Vollständiger Name | reticulocalbin 2, EF-hand calcium binding domain |
| Berechnetes Molekulargewicht | 37 kDa |
| Beobachtetes Molekulargewicht | 55 kDa |
| GenBank-Zugangsnummer | BC004892 |
| Gene symbol | RCN2 |
| Gene ID (NCBI) | 5955 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Protein-A-Reinigung |
| Lagerungspuffer | PBS only |
| Lagerungsbedingungen | Store at -80°C. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
Reticulocalbin-2 (RCN2) is also named as endoplasmic reticulum Ca2+-binding protein of 55 kDa (ERC55) and E6-binding protein (E6BP). It is strictly located in endoplasmic reticulum (PMID: 34094681). RCN2 is a low-affinity Ca2+ binding protein localized to the secretory pathway of mammalian cells, belongs to a member of the EF-hand Ca2+ binding protein family, which participate in the secretory process, chaperone activity, signal transduction as well as participation in a large variety of disease processes (PMID: 19260022). As for cancer research, several studies showed that RCN2 was related to tumor progression, such as mammary cancer, cervical cancer, neck squamous cell carcinoma and colorectal cancer (PMID: 16351756, PMID: 32422974). RCN2 played a pivotal role in HCC pathogenesis through regulating activation of the epidermal growth factor receptor (EGFR) pathway and modulating epidermal growth factor receptor EGFR dimerization and internalization (PMID: 28745317).









